As expected, in our study, a statistically significantly lower rate of the HER2 phenotype was reported in Group BC+EN+ patients, providing additional insight for a specific hormone-sensitive carcinogenic pathway in patients with endometriosis. This evidence concerns the gene ERBB2 and breast cancer.